Anti-Hu PDPN (cancer type) Purified

*Miyazaki A, Nakai H, Sonoda T, Hirohashi Y, Kaneko MK, Kato Y, Sawa Y, Hiratsuka H: LpMab-23-recognizing cancer-type podoplanin is a novel predictor for a poor prognosis of early stage tongue cancer. Oncotarget 2018 Apr 20;9 (30) :21156-21165. , URL: https://pubmed.ncbi.nlm.nih.gov/29765527/, *Furusawa Y, Yamada S, Nakamura T, Sano M, Sayama Y, Itai S, Takei J, Harada H, Fukui M, Kaneko MK, Kato Y: PMab-235: A monoclonal antibody for immunohistochemical analysis against goat podoplanin. Heliyon 2019 Jul 10;5 (7) :e02063. doi: 10.1016/j.heliyon.2019.e02063, URL: https://pubmed.ncbi.nlm.nih.gov/31338471/

The mouse monoclonal antibody LpMab-23 recognizes an extracellular epitope on human cancer type PDPN, a transmembrane glycoprotein, serving as a prognostic marker of oral carcinoma. This antibody recognizes an altered glycosylation pattern that occurs on oral cancer cells and it shows minimal reactivity with the surrounding non-cancerous tissue.